Marsh & McLennan Companies, Inc. (MMC) is well-positioned for growth, leveraging strong Marsh and Guy Carpenter businesses and Consulting segment, new business generation and prudent acquisitions. Favorable earnings estimates indicate that the company is on the right track.Headquartered in New York, Marsh & McLennan is a massive insurance company with a market cap of $114 billion. With solid prospects, this Zacks Rank #3 (Hold) stock is deemed worthwhile for holding on to at the moment. In this analysis, we ...

Charles River Laboratories International, Inc. (CRL) expands its products and services across the drug discovery and early-stage development continuum through targeted partnerships and acquisitions. The company’s Research Models and Services (RMS) segment is gaining from strong revenues of small research models. Signs of stabilization and improved bookings in the Discovery and Safety Assessment (DSA) segment are encouraging. Yet, the adverse macroeconomic impacts and currency woes pose risks for the company ...

Virtu Financial, Inc. (VIRT) , a prominent name in the financial services space, is under scrutiny as analysts trim their earnings projections for 2025 and 2026. While the company extended its streak of earnings beat in the first quarter, sentiment has weakened due to downward revisions in forward estimates.The Zacks Consensus Estimate for Virtu Financial’s 2025 and 2026 adjusted earnings now stands at $3.97 and $3.83 per share, respectively, reflecting week-over-week declines of 0.5% and 1%. Though 2025 es ...

Pfizer (PFE) announced that it is in-licensing global development and commercialization rights, ex-China, to SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, from Chinese biotech, 3SBio.3SBio is already developing SSGJ-707 in China for non-small cell lung cancer (“NSCLC”), metastatic colorectal cancer, and gynecological tumors, with the first phase III study expected to begin this year.Unlike the currently available marketed products, which target only the PD-1 protein, SSGJ-707 targets two proteins ...

Western Digital Corporation (WDC) is driving a new era of storage innovation by advancing infrastructure solutions tailored for artificial intelligence/machine learning (AI/ML), software-defined storage (SDS) and disaggregated storage. With a focus on hyperscale cloud service providers (CSPs), enterprises and Storage-as-a-Service (STaaS) vendors, the company’s Platforms Business delivers both high-capacity JBODs (Just a Bunch of Disks) and high-performance EBOF (Ethernet Bunch of Flash) NVMe-oF solutions to ...

Company Overview - Illumina, Inc. (ILMN) has launched the DRAGEN version 4.4 software, which is described as the industry's most comprehensive secondary analysis solution, featuring out-of-the-box oncology applications for clinical research and enhanced accuracy for multiomics assays [1][2]. Product Features - DRAGEN v4.4 simplifies next-generation sequencing (NGS) analysis and expands capabilities for customers, with the University Hospital of Tübingen being an early adopter for advanced secondary analysis in whole-genome germline testing [2]. - The software offers "push-button" analysis for oncology workflows, including the first commercially available heme whole-genome sequencing (WGS) application and pipelines for molecular residual disease (MRD) and WGS analysis [5]. - DRAGEN v4.4 boasts a 30% increase in structural variant (SV) calling accuracy and introduces a personalized pangenome reference capability that enhances single-nucleotide variant and indel calling accuracy by 20% [6]. Market Performance - Following the announcement of DRAGEN v4.4, ILMN shares increased by 3.3%, closing at $82.95, indicating positive market sentiment towards the stock [3]. - Illumina currently has a market capitalization of $13.13 billion and an earnings yield of 5.2%, significantly higher than the industry's -33.3% yield, with an average earnings beat of 56.4% over the last four quarters [4]. Industry Prospects - The global NGS data analysis market was valued at $999.4 million in 2024 and is projected to grow at a compound annual growth rate of 23.1% by 2030, driven by increased use of sequencing platforms in clinical diagnostics [7].

Equinor ASA (EQNR) , a Norwegian integrated energy company, has made a final investment decision, in partnership with Poland’s Polenergia, for an offshore wind project in the Baltic Sea. Polenergia stated that the project involves the construction of two offshore wind farms, namely Baltyk 2 and Baltyk 3, off the Polish coast. Each of these farms is anticipated to have a generation capacity of 720 megawatts (MW).The total construction cost is expected to be approximately €6.4 billion. The project is set to b ...

Solid operations in challenging weather conditions • Landsvirkjun‘s profit from core operations for the first quarter of the year amounted to USD 91 million and cash flow from operations USD 104 million. • The Company’s financial position has never been stronger, the equity ratio is 67% and the net debt to EBITDA ratio is 1.4×. • Operating revenues increased compared with the same period of the prior year after a downturn following the record year 2023. Hörður Arnarson, CEO: „Following a temporary downturn ...

SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of West Pharmaceutical Services, Inc. (NYSE: WST) common stock between February 16, 2023 and February 12, 2025, inclusive (the “Class Period”), have until Monday, July 7, 2025 to seek appointment as lead plaintiff of the West Pharmaceutical class action lawsuit. Captioned New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., No. 25-cv-02285 (E.D. Pa.), the West Pharmaceutic ...

Back in 2021, Moderna (NASDAQ: MRNA ) shares traded for around $500 per share, so it is amazing to think that at that time, even just 100 shares of this stock would have set you back by about $50,000. However, since then, it seems likeLong-time stock market investor focused on strategic buying opportunities with dividend and value stocks. This investment strategy has resulted in a near 5 star rating on Tipranks.com and over 9,000 followers on Seeking Alpha. Follow me on Twitter for my latest trading ideas: ...